| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.16 | 0.02 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.28 | 0.02 |